A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib

Tadashi Kumamoto, Yuki Aoki, Tomoko Sonoda, Miho Yamanishi, Ayumu Arakawa, Masanaka Sugiyama, Nami Shirakawa, Sae Ishimaru, Yoshimasa Saito, Akiko Maeshima, Miho Maeda, Chitose Ogawa

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

5 Citaten (Scopus)

Samenvatting

Histiocytic sarcoma in advanced clinical stages is typically an aggressive neoplasm, with poor response to conventional chemotherapy. An 18-year-old male with refractory histiocytic sarcoma that had transformed from Rosai–Dorfman disease was admitted to our hospital. A pathogenic variant of MAP2K1 was detected by next-generation sequencing of tumor specimens. Affected regions showed excellent responses to the MEK inhibitor trametinib. It has been reported that RAS/MEK/ERK pathway is activated in many cases of histiocytic sarcoma. MEK inhibition may represent a useful treatment option in histiocytic sarcoma.

Originele taal-2Engels
Pagina's (van-tot)228-232
Aantal pagina's5
TijdschriftInternational Journal of Hematology
Volume109
Nummer van het tijdschrift2
DOI's
StatusGepubliceerd - 20 feb. 2019
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib'. Samen vormen ze een unieke vingerafdruk.

Citeer dit